Barrington Research Issues Positive Forecast for Haemonetics (NYSE:HAE) Stock Price

Haemonetics (NYSE:HAE) had its price target boosted by stock analysts at Barrington Research from $90.00 to $93.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research’s target price indicates a potential upside of 13.40% from the company’s previous close.

A number of other equities research analysts have also weighed in on HAE. Mizuho boosted their target price on Haemonetics from $75.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Raymond James Financial reiterated an “outperform” rating and issued a $90.00 price objective on shares of Haemonetics in a research report on Friday, November 14th. Needham & Company LLC lowered Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, December 15th. Robert W. Baird lifted their target price on shares of Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Finally, Citigroup lowered their price target on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $84.40.

Haemonetics Price Performance

Shares of Haemonetics stock opened at $82.01 on Monday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64. Haemonetics has a 52-week low of $47.31 and a 52-week high of $87.32. The company has a fifty day moving average of $77.66 and a 200-day moving average of $65.86. The stock has a market capitalization of $3.84 billion, a price-to-earnings ratio of 23.98, a price-to-earnings-growth ratio of 1.55 and a beta of 0.29.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The business had revenue of $327.32 million during the quarter, compared to the consensus estimate of $311.61 million. During the same period in the previous year, the firm posted $1.12 earnings per share. The firm’s revenue for the quarter was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Equities research analysts expect that Haemonetics will post 4.55 EPS for the current year.

Institutional Trading of Haemonetics

Several large investors have recently added to or reduced their stakes in the stock. True Wealth Design LLC lifted its position in Haemonetics by 6,700.0% during the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 335 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Haemonetics by 59.4% during the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 165 shares during the last quarter. Versant Capital Management Inc boosted its position in shares of Haemonetics by 216.4% in the 3rd quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 567 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Haemonetics by 20,925.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 837 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.